This morning, the Federal Circuit released a precedential opinion and a nonprecedential order. In the opinion, the court affirmed a judgment of the District of New Jersey in a patent case. In the order, the Federal Circuit dismissed an appeal. Here is the introduction to the opinion and a link to the dismissal.

Amgen Inc. v. Sandoz Inc. (Precedential)

Sandoz Inc. (“Sandoz”) appeals from a decision of the United States District Court for the District of New Jersey holding that claims 3 and 6 of Amgen Inc.’s (“Amgen”) U.S. Patent 7,427,638 (the “’638 patent”) and claims 1 and 15 of Amgen’s U.S. Patent 7,893,101 (the “’101 patent”) had not been shown to be invalid as obvious. Amgen cross-appeals from the district court’s decision holding that claims 2, 19, and 21 of its U.S. Patent 10,092,541 (the “’541 patent”) were shown to be invalid as obvious. For the reasons provided below, we affirm.